Chongqing Genrix Biopharmaceutical Co Ltd

688443

Company Profile

  • Business description

    Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

  • Contact

    No. 699, Maliu Avenue
    Area A, Building 2
    International Bio City
    Banan
    Chongqing401338
    CHN

    T: +86 2361758666

    http://www.genrixbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    743

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,830.103.700.04%
CAC 407,723.4727.200.35%
DAX 4024,073.67286.221.20%
Dow JONES (US)44,406.36422.17-0.94%
FTSE 1008,806.5316.38-0.19%
HKSE24,083.92196.090.82%
NASDAQ20,412.52188.59-0.92%
Nikkei 22539,711.29123.610.31%
NZX 50 Index12,759.715.24-0.04%
S&P 5006,229.9849.37-0.79%
S&P/ASX 2008,588.800.50-0.01%
SSE Composite Index3,489.5416.420.47%

Market Movers